Here’s how analysts see Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) after this past week.

July 17, 2017 - By Richard Conner

 Here's how analysts see Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) after this past week.
Investors sentiment is 1.07 in Q4 2016. Its the same as in 2016Q3. It has no change, as 59 investors sold Alexion Pharmaceuticals, Inc. shares while 167 reduced holdings. only 81 funds opened positions while 160 raised stakes. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported.
Ftb stated it has 278 shares. Bp Public Ltd Co accumulated 7,000 shares. Liberty Mutual Asset Management Incorporated holds 0.07% or 16,332 shares. 2,928 were accumulated by Meiji Yasuda Asset. Clearbridge Limited Co holds 1.91% or 689,877 shares. Atria Ltd Liability Corporation, a North Carolina-based fund reported 2,680 shares. Moreover, Eaton Vance has 0.27% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Jane Street Gp Llc owns 92,452 shares for 0.05% of their portfolio. Royal Bancorp Of Canada holds 0.01% or 182,977 shares in its portfolio. Proshare Limited Liability Company owns 195,782 shares or 0.27% of their US portfolio. Healthcor Limited Partnership holds 1.81% or 261,140 shares. Point72 Asset Mgmt Lp holds 398,200 shares or 0.34% of its portfolio. Robeco Institutional Asset Management Bv has invested 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Beacon invested in 1,868 shares or 0.04% of the stock. Chevy Chase Tru accumulated 188,821 shares or 0.12% of the stock.

Since February 6, 2017, it had 4 buys, and 23 sales for $230.27 million activity. MACKAY MARTIN sold $244,170 worth of stock. $131,357 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Miller Edward. 167 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares with value of $21,182 were sold by Carmichael Clare. Moriarty John B sold $21,182 worth of stock. Thiel Carsten sold $495,611 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, February 28. Another trade for 1,932 shares valued at $243,371 was made by Wagner Heidi L on Monday, February 6. Another trade for 1,574 shares valued at $206,841 was made by O’Neill Julie on Monday, February 27.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 24 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 17 have Buy rating, 0 Sell and 7 Hold. Therefore 71% are positive. Alexion Pharmaceuticals Inc. had 57 analyst reports since July 27, 2015 according to SRatingsIntel. SunTrust initiated the shares of ALXN in report on Thursday, January 7 with “Buy” rating. The company was maintained on Friday, September 23 by Jefferies. The stock has “Buy” rating by Suntrust Robinson on Thursday, January 7. Credit Suisse upgraded the shares of ALXN in report on Monday, July 11 to “Outperform” rating. The stock has “Perform” rating by Oppenheimer on Thursday, December 15. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Strong Buy” rating by Raymond James on Tuesday, September 1. The rating was upgraded by BMO Capital Markets on Friday, April 29 to “Outperform”. BMO Capital Markets maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, June 13 with “Buy” rating. The stock has “Outperform” rating by Leerink Swann on Monday, September 26. Stifel Nicolaus maintained it with “Buy” rating and $245 target in Friday, December 11 report. Below is a list of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) latest ratings and price target changes.

23/06/2017 Broker: Robert W. Baird Rating: Hold New Target: $145.0000 Maintain
23/06/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $157.0000 Maintain
14/06/2017 Broker: Oppenheimer Rating: Hold Maintain
14/06/2017 Broker: J.P. Morgan Rating: Hold
14/06/2017 Broker: Credit Suisse Rating: Buy
13/06/2017 Broker: BMO Capital Markets Rating: Buy New Target: $158.0000 Maintain
08/06/2017 Broker: Goldman Sachs Rating: Buy New Target: $142.0000
07/06/2017 Broker: Jefferies Rating: Hold New Target: $120.0000 Maintain
02/06/2017 Broker: Leerink Swann Rating: Buy New Target: $136.0000
25/05/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade

It closed at $126.71 lastly. It is down 18.12% since July 17, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $28.41 billion. The Firm is focused on the development and commercialization of therapeutic products. It has a 60.17 P/E ratio. The Company’s products include Soliris , Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Barrons.com which released: “Alexion Pharmaceuticals: Nothing to See Here?” on July 07, 2017, also Benzinga.com with their article: “Exclusive: Alexion Responds To Government Probe” published on July 06, 2017, Nasdaq.com published: “Alexion Pharma: CHMP Issues Positive Opinion For Soliris – Quick Facts” on June 23, 2017. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Seekingalpha.com and their article: “Alexion higher after posting Strensiq update” published on July 05, 2017 as well as Gurufocus.com‘s news article titled: “Factory Mutual Insurance Co Buys Alexion Pharmaceuticals Inc, SPDR Series …” with publication date: July 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: